[ * ] = certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the securities and exchange commission pursuant to rule 24b - 2 of the securities exchange act of 1934, as amended. exhibit 10. 30 second amendment to termination and license agreement this second amendment to termination and license agreement ( the “ second amendment ” ) is made and entered into as of december 21, 2016 by and between merck sharp & dohme corp., a new jersey corporation with a place of business at one merck drive, whitehouse station, nj 08889 ( “ merck ” ) and scynexis, inc., a delaware corporation with a principal place of business at 101 hudson street, suite 3610, jersey city, nj 07302 ( “ scynexis ” ). recitals whereas, scynexis and merck are parties to a termination and license agreement dated as of may 24, 2013 ( collectively the “ original agreement ” ) ; whereas, the parties entered into to a letter agreement dated as of december 3, 2014, which amends the terms for payment of certain milestones under section 5 of the agreement ( the “ first amendment ” ; the original agreement as amended by the first amendment are collectively referred to herein as the “ agreement ” ) ; and whereas, the parties desire to enter into this second amendment to amend or clarify the provisions of section 5 on the timing of payment of certain milestone payments under the agreement. now, therefore, merck and scynexis hereby agree as follows : 1. definitions. unless otherwise defined herein, capitalized terms used in this second amendment have the meanings assigned thereto in the agreement. 1. 2. new trials. 2. a. scynexis is seeking to initiate ( i ) a dose ranging trial identified as scy - 078 - 302 and entitled “ a multicenter, randomized, double - blind phase ii - iii study comparing scy - 078 [ intravenous followed by oral ] to standard - of - care [ intravenous followed by oral ] for candidemia and invasive candidiasis using an adaptive design approach ” ( the “ ic phase 2 / 3 trial ” ) and ( ii ) a trial identified as scy - 078 - 301 and entitled “ open - label study to evaluate the efficacy and safety of scy - 078 in patients with invasive fungal infections that are ref